BURLINGTON, Massachusetts--Keystone Dental, a company that is focused on the delivery of products to the oral health-care space, has announced the beginning of a five-year, multi-center study to evaluate the long-term success of Genesis, the Biomimetic Implant System.
The postmarket surveillance study will evaluate the long-term clinical and esthetic success of the Genesis Implant System.
"We are thrilled to kick off this much anticipated study," said Pascal Girin, president and CEO of Keystone Dental, "especially given the caliber of clinicians participating in the study, including Dr. Dennis P. Tarnow as the lead investigator. We see this postmarket study as an example of the commitment we have made to delivering strong clinical evidence to the dental community."
Oxford Finance provides $20 million growth capital loan to Keystone Dental
The study will be conducted at eight centers within the United States with a total expected enrollment of 120 patients. Genesis dental implants will be surgically placed and assessed at defined time points beginning one year post surgery.
Additional safety and performance endpoints for the Genesis Implant System will be evaluated, including changes in bone height and soft tissue aesthetic outcomes.
"We know the design of the Genesis Implant System offers a number of significant advantages including an advanced surface, an aggressive thread design, and the first-ever marketed pink implant collar and abutment to improve esthetic success," said Dr. Mariano Polack, DDS, MS, prosthodontist, "and this study will demonstrate how it behaves long term, which is incredibly important information to the practicing clinician."
For more information, go to www.keystonedental.com.
To comment on this topic, go to community.pennwelldentalgroup.com/.
ID 332158709 © Dmitriiavramchik | Dreamstime.com
Jacob Wackerhausen / 1847335308 / iStock / Getty Images Plus
